2013-09-15 17:54:07 - New Pharmaceuticals market report from Global Markets Direct: "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013"
Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of
data for the indicated disease.
Full Report Details at
- www.fastmr.com/prod/675184_amyotrophic_lateral_sclerosis_pipelin ..
* A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis.
* A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to Get this Report
* Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: Genzyme Corporation, Biogen Idec Inc., Questcor Pharmaceuticals, Inc., GlaxoSmithKline plc, Isis Pharmaceuticals, Inc., Oxford BioMedica plc, Amorfix Life Sciences Ltd., Novartis AG, Isotechnika Pharma Inc., Eisai Co., Ltd., Jeil Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Hadasit Medical Research Services & Development Ltd, BrainStorm Cell Therapeutics Inc., Aeolus Pharmaceuticals, Inc., Neuralstem, Inc., Nutra Pharma Corporation, Paladin Labs Inc., Cytokinetics, Inc, MediPost Co., Ltd., Ceregene, Inc., D-Pharm Ltd., SCYNEXIS, Inc., Snowdon Inc., Pharmagenesis, Inc., Trophos SA, NeuroNova AB, Q Therapeutics, Inc., Neurimmune Therapeutics AG, Reata Pharmaceuticals, Inc., KineMed, Inc., Cellceutix Corporation, Daval International Ltd., Maas Biolab, Kringle Pharma, Inc., Nexgenix Pharmaceuticals, LLC, M's Science Corporation, miRagen Therapeutics, Inc., Pharnext SAS, Neuraltus Pharmaceuticals, Inc., RhinoCyte, Inc., California Stem Cell, Inc., Varinel, Inc.
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Amyotrophic Lateral Sclerosis Overview
An Overview of Pipeline Products for Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Therapeutics under Development by Companies
Amyotrophic Lateral Sclerosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Amyotrophic Lateral Sclerosis Therapeutics - Products under Development by Companies
Amyotrophic Lateral Sclerosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Amyotrophic Lateral Sclerosis Therapeutics Development
Biogen Idec Inc.
Questcor Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Oxford BioMedica plc
Amorfix Life Sciences Ltd.
Isotechnika Pharma Inc.
Eisai Co., Ltd.
Jeil Pharmaceutical Co., Ltd.
Mitsubishi Tanabe Pharma Corporation
Hadasit Medical Research Services & Development Ltd
BrainStorm Cell Therapeutics Inc.
Aeolus Pharmaceuticals, Inc.
Nutra Pharma Corporation
Paladin Labs Inc.
MediPost Co., Ltd.
Q Therapeutics, Inc.
Neurimmune Therapeutics AG
Reata Pharmaceuticals, Inc.
Daval International Ltd.
Kringle Pharma, Inc.
Nexgenix Pharmaceuticals, LLC
M's Science Corporation
miRagen Therapeutics, Inc.
Neuraltus Pharmaceuticals, Inc.
California Stem Cell, Inc.
Amyotrophic Lateral Sclerosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
DP-460 - Drug Profile
fingolimod hydrochloride - Drug Profile
ISIS-SOD1Rx - Drug Profile
RTA-801 - Drug Profile
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.